



Opinion



Inavolisib: A Selective Inhibitor of Mutant PI3K α for the Treatment of Breast Cancer

Surya K. De*

Conju-Probe, San Diego, CA, USA

Received: April 30, 2025 | Revised: June 08, 2025 | Accepted: June 18, 2025 | Published online: June 30, 2025

Breast cancer is one of the deadliest cancers that occurs in women. It remains the most invasive and common cancer among women worldwide. In 2023, over 2.3 million new cases were reported, resulting in approximately 685,000 deaths globally.^{1,2} Despite early detection and current treatment options such as surgery, radiation therapy, chemotherapy, hormone-blocking therapy, targeted therapy, and immunotherapy, breast cancer remains the leading cause of cancer-related death in women.^{3–6} Breast cancer arises from several gene mutations. A significant percentage of breast cancers involve mutations in the phosphatidylinositol-3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog (AKT)/mammalian target of rapamycin (mTOR) pathway. Several PI3K inhibitors have been approved for treating various diseases. Alpelisib is currently the only selective PI3K α inhibitor targeting breast cancer approved by the U.S. Food and Drug Administration (FDA); however, it is associated with several severe treatment-related adverse events.

Several biological processes, such as cell growth and proliferation, cell survival, protein synthesis, and glycolytic metabolism, are regulated by the PI3K/AKT/mTOR signaling cascade.^{7,8} PI3K is a class of lipid kinases composed of two subunits: the regulatory p85 and catalytic p110.⁹ The hyperactivation of this pathway induces and supports tumor growth.^{10,11} Class I PI3K has four isoforms: α , β , γ , and δ . Among these, PI3K α is frequently overexpressed in cancer cells through gene amplification or mutation of the *PIK3CA* gene.^{7,11–13} Indeed, PI3K α hyperactivation occurs in approximately 29% of all breast cancers and 40% of hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)-breast cancer. The most common *PIK3CA* gene mutations are E545K and H1047R, with H1047R located in the catalytic region. Therefore, isoform-selective small-molecule PI3K inhibitors have gained significant interest in drug discovery for cancer treatment. Nevertheless, preclinical studies have demonstrated some drawbacks of PI3K pathway inhibition. The inhibition of PI3K signaling releases negative feedback, leading to activation of receptor tyrosine kinase signaling. This reactivation reengages the pathway, reducing drug efficacy. Additionally, most approved PI3K inhibi-

tors also inhibit other signaling molecules such as AKT, mitogen-activated protein kinase (MAPK), tumor necrosis factor alpha (TNF α), C-X-C chemokine receptor type 4 (CXCR4), and CXCR5 in cell-based assays. Consequently, many PI3K inhibitors cause severe adverse events that may limit their clinical use. Scientists at Genentech have discovered a new class of compound that inhibits mutant PI3K signaling via HER2-dependent degradation of mutant p110 α .^{12,14–16}

Development of inavolisib

Investigators from Genentech previously reported the discovery of taselisib as a PI3K α inhibitor (Fig. 1).^{17,18} However, taselisib also inhibits PI3K δ and shows only moderate selectivity over PI3K β and PI3K γ . The inhibition of PI3K δ causes gastrointestinal and other toxicities. They subsequently identified compound a, which has 22-fold selectivity for PI3K α over PI3K δ (Table 1). Compound a inhibits PI3K α (PI3K α -H1047R) mutant HCC1954 cells and HDQ-P1 cells (PI3K α wild-type). Introducing a polar group, such as trifluoromethyl on the triazole ring, resulted in compound b, which is more potent than compound a in biochemical assays. Replacing the oxygen linker with a cyclic nitrogen produced compound c, with a K_i of 26 picomolar, but its selectivity over PI3K δ was reduced to only eight-fold. This change also increased the topological polar surface area, potentially reducing the compound's cell permeability and bioavailability. Replacement of the aromatic triazole with an aliphatic oxygen-containing cyclic compound resulted in compound d, which exhibited greater selectivity over PI3K δ (46-fold). Moving from a cyclic proline carboxamide to an acyclic alanine carboxamide, along with optimal positioning of the difluoro group, led to the clinical candidate inavolisib, which has 361-fold selectivity against PI3K δ . Interestingly, these compounds also function as strong mutant p110 α degraders.¹⁹

Physicochemical properties of inavolisib

Brand name: Itovebi; Chemical name: (2S)-2-[[[2-[(4S)-4-(difluoromethyl)-2-oxo-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide; Chemical formula: C₁₈H₁₉F₂N₅O₄; Molecular weight: 407.37; Topological polar surface area: 113 Å²; Hydrogen bond donor count: 3; Hydrogen bond acceptor count: 9; Freely rotatable bond count: 5; Heavy atom count: 29; Number of rings: 4; LogD (pH 7.4): 0.8; Solubility: 38

Keywords: Breast cancer; Inavolisib; PI3K degrader; Pharmacokinetics; Drug metabolism; Adverse events.

*Correspondence to: Surya K. De, Conju-Probe, San Diego, CA 92126, USA. ORCID: <https://orcid.org/0000-0001-5014-0798>. Tel: +1-8583374961, E-mail: desurya125@gmail.com

How to cite this article: De SK. Inavolisib: A Selective Inhibitor of Mutant PI3K α for the Treatment of Breast Cancer. *Oncol Adv* 2025;3(2):120–124. doi: 10.14218/OnA.2025.00012.




Fig. 1. Starting from taselisib and compound a to clinical candidate inavolisib.

$\mu\text{g/mL}$ (aqueous pH 7.4); Rule of 5 violations: 0.

The molecular weight below 500, hydrogen bond donors fewer than five, hydrogen bond acceptors fewer than 10, and LogP less than five comply with Lipinski's rule of 5. These characteristics suggest favorable oral absorption properties and oral bioavailability. Inavolisib does not violate Lipinski's rule of 5. Its aqueous solubility and lower surface area enhance its oral bioavailability.

Synthesis

The synthesis of inavolisib starts from compound 1, as shown in Figure 2. Compound 1 is coupled with compound 2 in the presence of copper iodide and potassium carbonate in dioxane at 100°C to

afford compound 3 in 50% yield.¹⁹ The bromo group in compound 3 is replaced by alanine in a copper iodide-mediated reaction in dimethyl sulfoxide to give compound 4. The final step converts the carboxylic acid to carboxamide, producing inavolisib in 46% yield over the last two steps. After successful synthesis and biochemical characterization, inavolisib was selected for clinical trials to determine dose and route of administration.

Dosage and administration

The recommended dose is 9 mg orally once daily, with or without food. Treatment continues until disease progression or unacceptable toxicities occur. For adverse events or intolerance, the dose can

Table 1. Selectivity of some compounds

Compound	PI3K α K _i (nM)	Selectivity PI3K δ /PI3K α times	HCC1954 pPRAS40 EC ₅₀ (nM)	Ratio HDQ-P1/HCC1954	TPSA in Å ²	LogD pH 7.4
Taselisib	0.090	1	24	2.3	118	2.3
a	0.346	22	89	1.4	110	1.9
b	0.188	14	ND	ND	110	2.2
c	0.026	8	ND	ND	130	1.5
d	0.043	46	ND	ND	ND	0.8
Inavolisib	0.034	361	19	4.4	113	0.8

HCC1954, hamon cancer center 1954 cell line; ND, not determined; PI3K, phosphatidylinositol-3 kinase; pPRAS40, phosphorylated proline-rich Akt Substrate of 40 kDa; TPSA, topological polar surface area.




Fig. 2. Reagents and Conditions: (a) CuI, K₂CO₃, dioxane, 100°C, 16 h, 50%; (b) L-Alanine, CuI, K₃PO₄, DMSO, 100°C, 2 h; (c) NH₄Cl, HATU, DIEA, DMF, rt, 1 h, 46%.

be reduced to 6 mg daily, with a second reduction to 3 mg daily. The exposure-response relationship for inavolisib's efficacy (pharmacodynamics) has not been fully reported. The time course of its pharmacodynamic response is unclear. No significant changes in cardiac electrophysiology were observed in clinical trials [Clinical trial number: NCT04191499].

Mechanism of action of inavolisib

Inavolisib is a selective PI3K α inhibitor that blocks phosphorylation of downstream AKT, resulting in inhibition of cell proliferation and induction of apoptosis in *PIK3CA*-mutated breast cancer cell lines. It also reduces tumor growth in *PIK3CA*-mutated, estrogen receptor-positive breast cancer xenograft models. Inavolisib, in combination with palbociclib and fulvestrant, demonstrates increased tumor growth inhibition compared to each treatment alone or doublet combinations. It inhibits two mutations, *PIK3CAE545K* and *PIK3CAH1047R*, although these mutations occur in different regions of the protein. This suggests that a global conformational change may occur in the presence of these activating mutations.

The efficacy of inavolisib was confirmed in a randomized (1:1), double-blind, placebo-controlled clinical trial (NCT04191499) in patients with *PIK3CA*-mutated, HR-positive, HER2-negative breast cancers. The median progression-free survival was 15 months for the inavolisib group compared to 7.3 months for the placebo plus palbociclib and fulvestrant group.

Binding mode

The X-ray crystal structure of inavolisib in complex with PI3K- α (PDB code: 8EXV) reveals that it binds in the adenosine triphosphate site (Fig. 3). The fluorine atom forms a hydrogen bond with Ser774.¹⁹ The oxygen atom in the oxazolidinone moiety forms

a hydrogen bond with Asp810. The oxygen atom of the benzoxazepine forms a hydrogen bond with Trp780. The NH on phenyl forms a hydrogen bond with Arg770. The carboxamide moiety forms three hydrogen bonding interactions with the primary amide of Gln859 and the backbone carbonyl of Ser854.

Pharmacokinetics

Absorption

The T_{max} of inavolisib is 3 h, and its absolute bioavailability is 76%.¹⁵

Distribution

The steady-state oral volume of distribution of inavolisib is 155 L. It is 37% bound to human plasma proteins.






Fig. 3. Hydrogen bonding interactions of inavolisib with phosphoinositide 3-kinase alpha (PI3K α).

Table 2. Comparison between alpelisib and inavolisib: selectivity, efficacy, and adverse events

Inhibitor	Apelisib	Inavolisib
Chemical structure		
Selectivity PI3K δ /PI3K α (times)	60	361
Dosage	300 mg orally daily	9 mg orally daily
Half-life	8 h	15 h
Objective response rate (ORR)	36%	94%
Median progression-free survival (PFS)	11 months	15 months
Adverse event (Grade \geq 3) in patients (%)	Stomatitis (2.5%); Diarrhea (7%); Nausea (2.6%); Vomiting (1%); Headache (1%); Abdominal pain (1.7%); Fatigue (5%); Rash (20%); Dry skin (0.5%); Decreased appetite (1%); Urinary tract infection (0.7%); Weight decreased (5%)	Stomatitis (6%); Diarrhea (3.7%); Nausea (0.6%); Vomiting (0.6%); Headache (0%); Fatigue (1.9%); Rash (0%); Dry skin (0%); Decreased appetite (0%); Urinary tract infection (0%); Weight decreased (3%)

Elimination

The elimination half-life of inavolisib is 15 h, and its oral clearance is 8.8 L/h. The long half-life helps reduce the dosing interval and prevents excessive accumulation that could lead to toxicity.

Metabolism

Inavolisib is predominantly metabolized in the liver by cytochrome P450 3A family. It conjugates with stercobilin, a product of heme catabolism.²⁰

Excretion

Following a single radiolabeled oral dose, 48% of inavolisib is recovered via feces (11% unchanged) and 49% via urine (40% unchanged).

Adverse reactions

During the clinical trial [NCT04191499], some adverse reactions (>10%) associated with inavolisib were observed, including headache, nausea, vomiting, diarrhea, stomatitis, fatigue, rash, dry skin, urinary tract infection, and decreased appetite. These adverse reactions were mild in severity (grade 1 or 2; no grade 3 or higher) and were manageable.

FDA-approved PI3K inhibitors include idelalisib, duvelisib, copanlisib, alpelisib, umbralisib, and leniolisib. Most of these inhibitors received accelerated approval based on single-arm clinical trials. However, randomized studies have shown a decrease in overall survival and an increase in fatal and severe adverse reactions. Consequently, idelalisib, copanlisib, duvelisib, and umbralisib have been withdrawn from the market due to concerns about severe adverse reactions and failure to meet efficacy expectations in confirmatory randomized, double-blind, placebo-controlled clinical trials. Alpelisib, a thiazole derivative, is a PI3K α inhibitor with moderate selectivity over PI3K δ (60-fold). Inhibition of PI3K δ can cause gastrointestinal and other toxicities. Inavolisib is more selective for PI3K α over PI3K δ (361-fold) and is there-

fore considered safer than other PI3K inhibitors. Indeed, alpelisib, used for breast cancer treatment, is associated with several grade 3 adverse reactions (Table 2). In contrast, inavolisib treatment did not show any treatment-related grade 3 adverse reactions such as rash (0%), dry skin (0%), decreased appetite (0%), or urinary tract infection (0%). Moreover, inavolisib, which has a unique chemical structure, is both a selective PI3K α inhibitor and a PI3K α mutant degrader. Due to this novel mechanism of action, inavolisib demonstrates prolonged and durable target inhibition, strong efficacy, a long half-life, and manageable adverse side effects (Table 2) compared to alpelisib. Other FDA-approved PI3K inhibitors cause gastrointestinal toxicity due to inhibition of the PI3K δ isoform. Inavolisib preferentially inhibits PI3K α mutants over the wild type. Therefore, previously approved PI3K α wild-type inhibitors cause insulinemia and hyperglycemia. Several PI3K inhibitors, such as taselisib, GNE-326, GNE-102, pictilisib, and GNE-181, are clinical candidates or in preclinical stages. These inhibitors are not sufficiently selective against PI3K δ compared to inavolisib, which is 361 times selective. Their half-lives are shorter than those of inavolisib. Additionally, their higher dose ranges contribute to increased systemic toxicities.

Investigators from Genentech developed inavolisib as a selective PI3K α inhibitor and a weak degrader of mutant PI3K α for breast cancer treatment. Jauslin et al. reported it as a strong PI3K α degrader.¹⁰ Currently, inavolisib alone or in combination with other drugs is undergoing clinical trials.^{21–23} This mini perspective summarizes inavolisib's physicochemical properties, synthesis, mechanism of action, binding mode, pharmacokinetics, and treatment-emergent adverse events.

Acknowledgments

None.

Funding

None.

Conflict of interest

Surya K. De has been an editorial board member of *Oncology Advances* since 2023. The author has no other conflicts of interest to disclose.

Author contributions

SKD is the sole author of the manuscript.

References

- [1] World Health Organization. WHO News Room, Fact sheets, Breast cancer. Geneva: World Health Organization; 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>. Accessed April 2, 2025.
- [2] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2024;74(3):229–263. doi:10.3322/caac.21834, PMID:38572751.
- [3] Singh A, Mishra R, Mazumder A. Breast cancer and its therapeutic targets: A comprehensive review. *Chem Biol Drug Des* 2024;103(1):e14384. doi:10.1111/cbdd.14384, PMID:37919259.
- [4] Garg P, Ramisetty S, Nair M, Kulkarni P, Horne D, Salgia R, et al. Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. *Biochem Pharmacol* 2025;236:116850. doi:10.1016/j.bcp.2025.116850, PMID:40049296.
- [5] De SK. Fundamental of cancer detection; treatment; and prevention. Weinheim: Wiley; 2022:151–191.
- [6] Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Discov* 2014;13(2):140–156. doi:10.1038/nrd4204, PMID:24481312.
- [7] Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304(5670):554. doi:10.1126/science.1096502, PMID:15016963.
- [8] Peng R, Zhan Y, Li A, Lv Q, Xu S. Research progress and development strategy of PI3K inhibitors for breast cancer treatment: A review (2016-present). *Bioorg Chem* 2024;153:107934. doi:10.1016/j.bioorg.2024.107934, PMID:39509786.
- [9] Barile E, De SK, Carlson CB, Chen V, Knutzen C, Riel-Mehan M, et al. Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway. *J Med Chem* 2010;53(23):8368–8375. doi:10.1021/jm100825h, PMID:21062009.
- [10] Jauslin WT, Schild M, Schaefer T, Borsari C, Orbegozo C, Bissegger L, et al. A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3K α . *Chem Sci* 2024;15(2):683–691. doi:10.1039/d3sc04629j, PMID:38179525.
- [11] Wang S, Liu C, Yang C, Jin Y, Cui Q, Wang D, et al. PI3K/AKT/mTOR and PD-1/CTLA-4/CD28 pathways as key targets of cancer immunotherapy (Review). *Oncol Lett* 2024;28(6):567. doi:10.3892/ol.2024.14700, PMID:39390982.
- [12] Song KW, Edgar KA, Hanan EJ, Hafner M, Oeh J, Merchant M, et al. RTK-Dependent Inducible Degradation of Mutant PI3K α Drives GDC-0077 (Inavolisib) Efficacy. *Cancer Discov* 2022;12(1):204–219. doi:10.1158/2159-8290.CD-21-0072, PMID:34544753.
- [13] Menteş M, Karakuzulu BB, Uçar GB, Yandım C. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3K α specific inhibitors and ATP. *Comput Biol Chem* 2022;99:107726. doi:10.1016/j.compbiolchem.2022.107726, PMID:35842959.
- [14] Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. *N Engl J Med* 2024;391(17):1584–1596. doi:10.1056/NEJMoa2404625, PMID:39476340.
- [15] Salphati L, Pang J, Plise EG, Cheong J, Braun MG, Friedman LS, et al. Preclinical assessment of the PI3K α selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human. *Xenobiotica* 2024;54(10):808–820. doi:10.1080/00498254.2024.2415103, PMID:39387185.
- [16] Jhaveri KL, Accordini MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, et al. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. *J Clin Oncol* 2024;42(33):3947–3956. doi:10.1200/JCO.24.00110, PMID:39236276.
- [17] Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, et al. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. *Clin Cancer Res* 2018;24(18):4380–4387. doi:10.1158/1078-0432.CCR-18-0613, PMID:29793946.
- [18] Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A Phase Ib Study of Alpelisib (BYL719), a PI3K α -Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. *Clin Cancer Res* 2017;23(1):26–34. doi:10.1158/1078-0432.CCR-16-0134, PMID:27126994.
- [19] Hanan EJ, Braun MG, Heald RA, MacLeod C, Chan C, Clausen S, et al. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degradator of Mutant PI3K α . *J Med Chem* 2022;65(24):16589–16621. doi:10.1021/acs.jmedchem.2c01422, PMID:36455032.
- [20] Cho S, Cheruzel L, Cai J, Wrigley SK, Gemmell RT, Kokubun T, et al. Discovery of Unprecedented Human Stercobilin Conjugates. *Drug Metab Dispos* 2024;52(9):981–987. doi:10.1124/dmd.124.001725, PMID:38991780.
- [21] Bedard PL, Jhaveri KL, Accordini MK, Cervantes PA, Gambardella V, Hamilton E, et al. Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. *Eur J Cancer* 2025;221:115397. doi:10.1016/j.ejca.2025.115397, PMID:40203765.
- [22] Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, et al. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. *Clin Cancer Res* 2024;30(16):3549–3563. doi:10.1158/1078-0432.CCR-23-3465, PMID:38819400.
- [23] Vanhaesebroeck B, Burke JE, Madsen RR. Precision Targeting of Mutant PI3K α in Cancer by Selective Degradation. *Cancer Discov* 2022;12(1):20–22. doi:10.1158/2159-8290.CD-21-1411, PMID:35022207.